|
|
Post by lcd on Nov 5, 2014 14:02:08 GMT
|
|
|
|
Post by JHam on Nov 5, 2014 14:30:38 GMT
|
|
|
|
Post by JHam on Nov 13, 2014 9:34:06 GMT
Just a reminder that the conference call is today at 8:30 am est. We should be getting a PR in a few hours as well.
|
|
|
|
Post by lcd on Nov 13, 2014 13:27:28 GMT
|
|
|
|
Post by lcd on Nov 13, 2014 13:50:27 GMT
Some streaming notes from the call...
14 subject Israel study is complete and starting next week they will parse through the data with plans to release full results at a conference next year. They are confident that full results will be similar to the interim results already released.
Tony said they plan to conduct studies with cryopreserved cells next year and multi-dosetolerance studies that along with the P2 trial will be used to work with FDA in 2016 to design pivotal study.
They took multiple questions, some on the Israel trial details, one trying to nail down the data release dates (Tony mentioned a manuscript in the works and top level results in the next few weeks with full results at a conference next year).
Tony seems like a real professional and did express his excitement about Nurown's prospects for ALS and other diseases.
|
|
|
|
Post by tradeup on Nov 13, 2014 17:17:43 GMT
Some streaming notes from the call... 14 subject Israel study is complete and starting next week they will parse through the data with plans to release full results at a conference next year. They are confident that full results will be similar to the interim results already released. Tony said they plan to conduct studies with cryopreserved cells next year and multi-dosetolerance studies that along with the P2 trial will be used to work with FDA in 2016 to design pivotal study. They took multiple questions, some on the Israel trial details, one trying to nail down the data release dates (Tony mentioned a manuscript in the works and top level results in the next few weeks with full results at a conference next year). Tony seems like a real professional and did express his excitement about Nurown's prospects for ALS and other diseases. Thank you for the notes, LCD. Liking the current MC here with a near-term catalyst. |
|
|
|
Post by lcd on Nov 13, 2014 17:41:25 GMT
tradeup,
I hope the top level results catalyst does happen but I thought it was odd he didn't mention it in the formal presentation when he only mentioned a conference in 2015. I like this company and its CEO and think the market cap will grow significantly next year but I am deep in the red right now and could use a price spike to make me feel better.
|
|
|
|
Post by JHam on Nov 13, 2014 18:23:17 GMT
Just listened to the call. Here are my notes. A lot of it reiterates what lcd has shared:
- 13 patients have been treated to date with either cells or placebo in Phase 2
- Long waiting list to participate in trial
- The last patient in Phase 2a had their final check-up before the end of Q3. Data is in hand and their statisticians are going through it as fast as they can.
- They plan to publish the data on all 14 patients and present it at a conference in early 2015
- Will launch a re-dose trial using cryopreserved cells in 2015 and plan to share the results with the FDA in 2016 to discuss the design for a pivotal trial
- $10.6M cash on hand at end of Q3
Q & A highlight
- "Final top-line results" to be released "in the coming weeks", "subsequent to that, full presentation at a medical conference"
|
|
|
|
Post by dayanand33 on Nov 13, 2014 23:01:51 GMT
|
|
|
|
Post by tradeup on Nov 13, 2014 23:27:30 GMT
|
|
|
|
Post by dayanand33 on Nov 14, 2014 2:59:28 GMT
Just listened to the call. Here are my notes. A lot of it reiterates what lcd has shared: - 13 patients have been treated to date with either cells or placebo in Phase 2 - Long waiting list to participate in trial - The last patient in Phase 2a had their final check-up before the end of Q3. Data is in hand and their statisticians are going through it as fast as they can. - They plan to publish the data on all 14 patients and present it at a conference in early 2015 - Will launch a re-dose trial using cryopreserved cells in 2015 and plan to share the results with the FDA in 2016 to discuss the design for a pivotal trial - $10.6M cash on hand at end of Q3 Q & A highlight - "Final top-line results" to be released "in the coming weeks", "subsequent to that, full presentation at a medical conference" At 5:09 min the message states that data from almost all the phase 2a patients was already shared in the June conference. "We don't expect any important shift in the top line results" audio.viavid.com/20141113-111791-brainstorm.mp3It seems like there won't be any surprise element in the top line results. |
|
|
|
Post by JHam on Nov 14, 2014 3:05:02 GMT
Just listened to the call. Here are my notes. A lot of it reiterates what lcd has shared: - 13 patients have been treated to date with either cells or placebo in Phase 2 - Long waiting list to participate in trial - The last patient in Phase 2a had their final check-up before the end of Q3. Data is in hand and their statisticians are going through it as fast as they can. - They plan to publish the data on all 14 patients and present it at a conference in early 2015 - Will launch a re-dose trial using cryopreserved cells in 2015 and plan to share the results with the FDA in 2016 to discuss the design for a pivotal trial - $10.6M cash on hand at end of Q3 Q & A highlight - "Final top-line results" to be released "in the coming weeks", "subsequent to that, full presentation at a medical conference" At 5:09 min the message states that data from almost all the phase 2a patients was already shared in the June conference. "We don't expect any important shift in the top line results" audio.viavid.com/20141113-111791-brainstorm.mp3It seems like there won't be any surprise element in the top line results. Agreed. Which is good from the perspective that that was pretty encouraging data, but not good if you were looking for a nice pop on this data release. |
|
|
|
Post by JHam on Nov 14, 2014 3:07:50 GMT
Which honestly is not a big deal for me since BCLI is basically a buy and hold stock for me. There is still great long term valuation to be had with this one in my opinion even with potential dilution looming in the future.
|
|
